PGENNasdaqPharmaceutical PreparationsFiscal year ends December 31
PRECIGEN, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026
$6.66+0.28 (+4.31%)
Close on Oct 19, 2026
- Market cap
- $2.76B
- P/E (TTM)
- –
- Dividend yield
- –
PRECIGEN, INC. revenue by segment
By business segment
| Revenue | Q2 26 | Q1 26 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | Q2 23 | Q1 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reportable Segments | $54.98M | – | $856.00K | – | – | – | – | – | – | – | $1.77M | $1.85M | 100.0% | +6322.7% |
| Trans Ova | – | – | – | – | – | – | – | – | – | – | – | $1.85M | – | – |
| Exemplar | – | – | – | $1.07M | $1.19M | $953.00K | $717.00K | $1.07M | $1.15M | $1.38M | $1.77M | $1.85M | – | – |
| Biopharmaceuticals | – | – | – | $1.34M | – | – | – | – | $75.00K | $0 | $0 | $0 | – | – |
By product or service
| Revenue | Q2 26 | Q1 26 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | Q2 23 | Q1 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Product revenues, net | $53.26M | $21.83M | $41.00K | $203.00K | – | – | – | – | – | – | – | – | 96.9% | +129807.3% |
| Papzimeos | $53.07M | $21.59M | $0 | $0 | – | – | – | – | – | – | – | – | 96.5% | – |
| Service revenues | $1.72M | $1.42M | $815.00K | $1.14M | – | – | – | – | – | – | – | – | 3.1% | +110.6% |
| Exemplar | $192.00K | $237.00K | $41.00K | $203.00K | – | – | – | – | – | – | – | – | 0.3% | +368.3% |
By region
From the segment and revenue-disaggregation notes of Precigen's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.